Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with melanoma that has spread to the liver, confirmed by a liver biopsy showing melanoma cells.
- You have not yet received systemic (whole-body) treatment for your advanced or metastatic melanoma — although previous adjuvant (preventive) treatment with certain immunotherapy or targeted therapy drugs is allowed, as long as it finished more than 6 months ago.
- Your cancer can be measured or tracked using standard imaging scans.
- Your organs (such as kidneys, liver, and heart) are functioning well enough, based on blood tests taken within 28 days before signing up.
- You weigh at least 35 kilograms (about 77 pounds), due to physical requirements of the procedure used in this trial.
Who may not be able to join:
- You have previously been treated with the drug HEPZATO KIT™, or with the combination drug nivolumab and relatlimab (also known as Opdualag™).
- You have had a serious (Grade 3 or higher) immune-related side effect from a previous immunotherapy drug that caused you to stop treatment — unless you were later able to restart that type of therapy without the serious side effect returning.
- You currently have brain metastases (cancer spread to the brain) that are causing symptoms or are not under control, or you have cancer affecting the lining of the brain or spinal cord that has not been treated with surgery or radiation.
- You are currently taking prednisone (a steroid medication) at a dose of 10 mg per day or more, or an equivalent steroid medication.
- You have received an organ transplant.
(Note: Radiotherapy within 30 days before starting the trial may be permitted in certain circumstances — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Vincent Ma, MD, UW Carbone Cancer Center
Phone: 800-622-8922
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and Severity of Dose Limiting Toxicities (DLTs); Incidence of Treatment-Emergent Adverse Events; Incidence of Serious Treatment-Emergent Adverse Events; Number of Participants that Discontinue Treatment due to Adverse Events; Overall Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.